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INTRODUCTION
A diet rich in natural antioxidants supports health1,2 
strengthens the antioxidant network and is thereby 
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ABSTRACT
Aim and Background: Astaxanthin is a unique carotenoid of predominantly marine origin providing the pink-red color to certain 
microalgae and accumul ating in various animals higher in the food chain. It is an antioxidant without pro-oxidant properties or known 
side-effects following oral intake. Materials and Methods: We investigated astaxanthin kinetics in plasma and erythrocytes (red 
blood cells [RBC]) of four healthy adults after a single oral 40 mg dose. Plasma- and RBC-astaxanthin were measured during 
72 h. Subsequently, an 8 mg/day dose was given during 17 days. Plasma- and RBC-astaxanthin were measured each morning. 
Results: Plasma-astaxanthin reached a peak (from 79 to 315 nmol/L) after 8 h and then declined (half-life, 18 h). Within 72 h, 
plasma-astaxanthin had returned to baseline. RBC-astaxanthin reached a peak (from 63 to 137 nmol/L packed cells) at 12 h and 
subsequently disappeared (half-life, 28 h). During the daily dose, plasma-astaxanthin increased until day 10 (187 nmol/L) and then 
decreased to a steady concentration similar to that reached after 2 days. RBC-astaxanthin appeared to be highly variable (group 
median concentration, 86 nmol/L packed cells). Conclusion: We found high intra- and inter-individual variations, especially in 
RBC, possibly due to non-standardized time difference between astaxanthin intake and sampling, fl uctuating background intake 
from the diet, variable bioavailability, large distribution volume, degradation or others. Oral astaxanthin is rapidly absorbed and 
incorporated into RBC. The subsequent rapid decline suggests that, for a higher-than-baseline status, astaxanthin should be 
taken daily, at least in an early phase when total body equilibrium, if any, has not been reached yet.
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associated with lower oxidative stress and infl ammation, 
leading to decreased risk of  cardiovascular disease, 
neurodegenerative diseases, certain cancers, and other 
diseases.3 Astaxanthin has recently received attention for its 
potent antioxidant activity4 without pro-oxidant properties.5 
It is a unique carotenoid belonging to the xanthophyll 
family, synthesized by plants and algae providing them with 
a pink-red color6 and accumulating in certain animals higher 
in the food chain, such as fl amingoes, salmon, shrimps, 
and crayfi sh.7 Natural astaxanthin is optically distinct from 
synthetic astaxanthin. It is commercially available as a food 
supplement from the algae Hematococcus pluvialis.8
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Orally administered astaxanthin incorporates into both 
plasma and erythrocytes (red blood cell [RBC]) of  healthy 
subjects, improves RBC antioxidant status and decreases 
membrane phospholipid peroxidation after a 12-week daily 
supplementation.9 Following its ingestion, astaxanthin has 
been shown to reach a peak in plasma at about 7 h and 
to decline with a median half-life of  about 21 h.10 The 
kinetics of  astaxanthin in RBC are currently unknown. We 
investigated the kinetics of  astaxanthin in both plasma and 
RBC after a single oral 40 mg dose and its distribution in both 
compartments during a 17-day 8 mg/day maintenance dose.
MATERIALS AND METHODS
Study group
Four apparently healthy volunteers (1 male, 3 females) aged 
29-41 years (weight 59-70 kg, height 1.73-1.80 m, individual 
body-mass indices, 19.7, 20.7, 22.1, and 22.9 kg/m2), 
participated in this pilot intervention study. Throughout 
the study period, subjects were instructed to maintain their 
usual lifestyle. Age, weight, and length were self-reported. 
All participants received verbal and written explanation of  
the objectives and procedure of  the study and subsequently 
provided us with written informed consent.
Astaxanthin supplementation
The pilot study consisted of  two well-defi ned parts. In 
the fi rst part, a single dose of  40 mg astaxanthin (10 soft 
gel gelatin capsules containing an astaxanthin extract 
from the algae H. pluvialis; Cyanotech, Hawaii) was given 
to the 4 subjects together with a fat-containing breakfast, 
as astaxanthin absorption is improved in the presence of  
lipid based formulations.11 Each soft gel capsule contained 
4 mg astaxanthin, 10 IU vitamin E (as d-alpha tocopherol), 
64 μg β-carotene, 40 μg lutein and 72 μg canthaxanthin. 
The capsules contained glycerol and saffl ower oil as wetting 
and fi lling agents, respectively. Five days after, the 40 mg 
astaxanthin intake, the second part of  the pilot was initiated, 
where the four participants were instructed to take a daily 
dose of  8 mg astaxanthin during 17 days. The astaxanthin 
capsules were taken in the evening together with, or just 
after, a fat-containing meal. Compliance was verbally 
checked by one of  us on the following day.
Sample collection and analyses
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated 
blood (4 mL) was collected in the morning by venipuncture 
at baseline and at 2, 4, 6, 8, 10, 12, 24, 32, 48, and 72 h 
after the single oral 40 mg astaxanthin dose and every 
morning for 13 days (days 1-5, 8-12, and 15-17, respectively) 
following the daily 8 mg maintenance dose.
Ethylenediaminetetraacetic acid-blood was centrifuged 
for 10 min at 1,000 g in a cooled centrifuge (4°C) for the 
separation of  plasma and RBC. The EDTA-plasma (200 μL) 
was transferred to a tefl on-sealable sovirel tube containing 
2.75 mL of  an antioxidant solution containing EDTA, 
ascorbic acid, pyrogallol and butylated hydroxytoluene 
in methanol/water for the preservation of  astaxanthin. 
Following the removal of  plasma and buffy coat, RBC were 
washed 3 times with 0.9% saline. Phosphate buffered saline 
(pH = 7.4) was subsequently added to prepare an about 50% 
hematocrit suspension, from which 500 μL were transferred 
to a tefl on-sealable sovirel tube containing 2.75 mL of  
the aforementioned antioxidant solution. The remainder 
was used for a total cell count including a hematocrit 
measurement (Sysmex, Etten-Leur, The Netherlands).
All tubes were frozen at −20°C until analyses. Plasma- and 
RBC-astaxanthin were determined with high-performance 
liquid chromatography (HPLC)/VIS using previously 
described procedures.12,13 Briefl y, this method includes 
hexane extraction, evaporation to dryness under nitrogen, 
and re-dissolution in methyl tert-butyl ether (MTBE) and 
ethanol. From this mixture, 50 μL are injected into the 
HPLC. The analytical system was composed of  a carotenoid 
250 × 2.1 mm ID column (YMC, Japan) with HPLC/VIS 
detection operated at a fl ow rate of  0.3 ml/min, using a 
gradient of  solvent A (methanol: MTBE: H2O = 81:15:4 
v/v/v) and solvent B (methanol: MTBE = 7:93 v/v) at a 
detection wavelength of  450 nm.
The RBC-astaxanthin content (in nmol/L packed cells) 
was calculated by dividing the measured RBC-astaxanthin 
concentration by the hematocrit of  the washed RBC 
suspension.
RESULTS
The between-ser ies  plasma-astaxanthin cycl ic 
voltammograms (CVs)(n = 6) at mean levels of  42 and 
111 nmol/L amounted to 5.3 and 3.8%, respectively, implying 
that the analytical reference change values (2.8 times the 
SDs of  2.2 and 4.2 nmol/L, respectively)14 are about 6 
and 12 nmol/L, at the low and higher levels, respectively.
Plasma- and RBC-astaxanthin kinetics after a 
single 40 mg oral dose
The individual and median courses of  plasma- and 
RBC-astaxanthin up to 72 h after the single 40 mg dose 
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are presented in Figure 1. Large intra- and inter-individual 
variations in the courses were observed for plasma- and 
notably for RBC-astaxanthin, (Panels A and B). Due to the 
variations in time to reach the peak values and also peak 
heights, and in view of  the small sample size, we refrained 
from statistical analyses. Nevertheless, all study subjects 
responded well beyond the analytical variation as their 
differences between baseline and peak levels were well 
beyond the reference change value for analytical variation.
In all four subjects, plasma-astaxanthin (Panel A) reached 
a peak (from a baseline median of  79-315 nmol/L) after 
8 h and subsequently declined with an estimated half-life 
of  18 h. Within 72 h, plasma-astaxanthin had returned to 
baseline (median, 64 nmol/L). This is in agreement with 
Østerlie et al., who reported a plasma-astaxanthin peak at 
about 7 h following a 100 mg astaxanthin oral dose and a 
half-life of  about 21 h.10 RBC-astaxanthin (Panel B) reached 
a peak (from 63 at baseline to 137 nmol/L packed cells) 
at 12 h and subsequently disappeared with a half-life of  
about 28 h. Individual summits were reached after 6, 8, 8, 
and 12 h. Furthermore for RBC, the baseline was reached 
within 72 h (median, 27 nmol/L packed cells). The median 
percentage astaxanthin found in RBC throughout the 
72 h observation period (with the plasma concentration 
set at 100%) amounted to 44% (range of  individual 
medians: 26-56%). These RBC-plasma ratios, subject to 
a large variation, are comparable to the median of  43% 
(range: 35-48%) that we estimated from the data from 
Nakagawa et al.9 who supplemented healthy adults with 6 
and 12 mg oral astaxanthin/day for 12 weeks.
Plasma- and RBC-astaxanthin during a 17 days 
8 mg/day oral maintenance dose
The individual and median courses of  plasma- and 
RBC-astaxanthin during the 17 days maintenance dose 
are presented in Figure 2. Supplementation started 5 days 
after the single 40 mg oral dose. Baseline levels were taken 
from astaxanthin concentrations at 72 h after the single 
40 mg astaxanthin oral dose. Plasma-astaxanthin (Panel A) 
increased slowly until day 10, reaching a maximum 
of  187 nmol/L. After this peak, plasma astaxanthin 
decreased to reach a steady concentration similar to that 
reached after 2 days. RBC-astaxanthin (Panel B) appeared 
to be highly variable, giving rise to a group median 
Figure 1: Courses of astaxanthin in plasma (a) and erythrocytes (b) after a single 40 mg astaxanthin oral dose. (Healthy subjects (n = 4) took 
a single 40 mg astaxanthin oral dose (from Haematococcus pluvialis; Cyanotech, Hawaii). Each soft gel capsule contained 4 mg astaxanthin, 
10 IU vitamin E (as d-alpha tocopherol), 64 μg β-carotene, 40 μg lutein and 72 μg canthaxanthin. Dotted lines represent data of the 4 individuals 
and the bold lines represents their medians. RBC: Red blood cell)
ba
Figure 2: Courses of astaxanthin in plasma (a) and erythrocytes (b) during a 17 days maintenance dose of 8 mg astaxanthin/day (Healthy subjects 
(n = 4) took a daily dose of 8 mg astaxanthin (from Haematococcus pluvialis; Cyanotech, Hawaii) during 17 days. Supplementation started 5 days 
after the single 40 mg oral dose. Baseline levels (day 1) were taken from the astaxanthin concentrations at 72 h after the single 40 mg astaxanthin 
oral dose [Figure 1]. Each soft gel capsule contained 4 mg astaxanthin, 10 IU vitamin E (as d-alpha tocopherol), 64 μg β-carotene, 40 μg lutein 
and 72 μg canthaxanthin. Dotted lines represent data of the 4 individuals and the bold lines represents their medians. RBC: Red blood cell)
ba
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concentration of  86 nmol/L packed cells throughout the 
17 days supplementation period. The median percentage 
astaxanthin found in RBC throughout the 17 days 
maintenance dose (with the plasma concentration set at 
100%) was 49% (range of  individual medians: 28-71%). 
This value is in agreement with the median of  44% (range 
of  individual medians: 26-56%) of  the study group 
throughout the 72 h observation period following the single 
40 mg dose (see above), and comparable to the median of  
43% (range: 35-48%) that we estimated from the data from 
Nakagawa et al.9 Large intra- and inter-individual variations 
were observed for plasma- and RBC-astaxanthin, notably 
for the latter, during the 17 days supplementation period. 
This may be partly due to the low dose compared with the 
background intakes (from food). For instance, the median 
inter-individual plasma-astaxanthin CV during the 17 days 
maintenance dose amounted to 20% (range: 3-46%), and 
for RBC-astaxanthin this CV was 40% (range: 22-212%).
DISCUSSION AND CONCLUSIONS
The short plasma- and RBC-astaxanthin half-lives of  18 and 
28 h, respectively, suggest the necessity to take astaxanthin 
on a daily basis to maintain a higher-than-baseline steady 
state, at least in the initial phase of  supplementation. This 
early phase might in part be infl uenced by the tendency of  
astaxanthin to incorporate into all bodily cell membranes. 
Astaxanthin is likely to be subject to a large distribution 
volume, in which probably not all compartments are 
reached at equal rates. Both the single and maintenance 
oral doses gave rise to large intra- and inter-individual 
biological variations, especially in the RBC compartment. 
The variability in responses may, e.g., derive from 
non-standardized time difference between astaxanthin 
intake and blood sampling, a fl uctuating background intake 
from the diet, variable bioavailability, large distribution 
volume, (induced) degradation and others. High intra- and 
inter-individual bioavailability of  carotenoids has been 
previously reported15-17 and the present data on astaxanthin 
appear as no exception to this rule.
Orally administered astaxanthin is rapidly absorbed and 
becomes rapidly incorporated into RBC. The subsequent 
rapid decline suggests that, for a higher-than-baseline 
status, astaxanthin should be taken daily, at least in an early 
phase when total body equilibrium, if  any, has not been 
reached yet.
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